Clinical trial · Interventional
Correlation Analysis of T-lymphocyte Subsets and Prognosis in Autologous Stem Cell Transplantation (ASCT) for Lymphoma
NCT03283111CI-TRIAL-00033995unknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a retrospective, single-center, non-randomized, non-controlled study. This study aims to explore the effect of T-lymphocyte subsets changes in immunologic reconstitution and prognosis in lymphoma patients who were treated by autologous stem cell transplantation.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lymphoma | Lymphoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| autologous stem cell transplantation | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- autologous stem cell transplantation
- description
- Lymphoma patients received autologous stem cell transplantation for the first time
- interventionNames
- Biological: autologous stem cell transplantation
Primary outcomes (2)
- measure
- Progression-free survival
- timeFrame
- 2 years
- description
- Progression-free survival serves as an effective index to analysis the correlation of T-lymphocyte subsets and prognosis. And it would be measured within 2 years.
- measure
- Overall survival
- timeFrame
- 2 years
- description
- The investigators would measure the overall survival of participants within 2 years. Overall survival serves as an effective index to analysis the correlation of T-lymphocyte subsets and prognosis.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 65 Years
Show eligibility criteria text
Inclusion Criteria: 1. Men and women≥18 years, \<65 years; 2. Lymphoma patients treated by autologous stem cell transplantation for the first time; 3. ECOG ≤ 2; 4. Ccr ≥ 50 ml/min; 5. ALT, AST and TBIL≤2.5-fold upper normal range; 6. Satisfactory heart and lung function; 7. Women of reproductive potential must have a negative pregnancy test. Male and female of reproductive potential must agree to practice birth control during the study and one year post study; 8. Good compliance and sighed informed consent voluntarily. Patients should be conformed to all inclusion criteria above. Exclusion Criteria: 1. Prior autologous/ allogeneic hematopoietic stem cell transplantation for lymphoma; 2. Senior or uncontrolled virus injection: HIV, TP, hepatitis virus; 3. Serious complications; 4. LVEF\<55%; 5. Atopy or allergy to biological product derived from colibacillus; 6. Women who are breastfeeding, pregnant or refused to practice contraception; 7. Severe mental or nervous system diseases; 8. Severe abnormalities of heart, lung and central nervous system symptoms; 9. Patients with sickle cell disease, erythronoclastic anemia or other hematological disease which has an impact on medullary hematopoiesis; 10. Enrolled in other study currently or 30 days before screen; 11. Patients, in the opinion of investigators, may not be eligible or are not able to comply with the study. Patients conformed to any of above criteria should be excluded from this study.
References
Publications (0)
Data not yet available
No reference posted for this study.